Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAL-101 in Mild to Moderate Alzheimer's Disease
NCT07789873Phase 2Not yet recruiting
- Sponsor
- Galimedix Therapeutics
- Start
- Feb 2027
- Primary completion
- Apr 2028
01
Overview
A Phase 2 trial of gal-101 in Alzheimer's disease (AD), sponsored by Galimedix Therapeutics. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
gal-101
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07789873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789873.